News for '-sun-pharma'

Sensex falls 344 pts amid profit-taking, foreign fund outflows

Sensex falls 344 pts amid profit-taking, foreign fund outflows

Rediff.com24 Oct 2025

Among Sensex firms, Hindustan Unilever dropped the most by 3.20 per cent. UltraTech Cement, Kotak Mahindra Bank, Adani Ports, Titan, HDFC Bank and Axis Bank were also among the laggards. However, Bharti Airtel, ICICI Bank, Bharat Electronics and Sun Pharma were among the gainers.

Sensex falls 388 points; Adani stocks rally

Sensex falls 388 points; Adani stocks rally

Rediff.com19 Sep 2025

Among Sensex firms, HCL Tech, ICICI Bank, Titan, Trent, Kotak Mahindra Bank, Hindustan Unilever, Mahindra & Mahindra and HDFC Bank were the major laggards. However, Adani Ports, Bharti Airtel, SBI, NTPC and Sun Pharma were among the gainers.

Sensex ends above 83K buoyed by US Fed rate cut

Sensex ends above 83K buoyed by US Fed rate cut

Rediff.com18 Sep 2025

Among Sensex firms, Eternal, Sun Pharma, Infosys, HDFC Bank, HCL Tech, Hindustan Unilever, Power Grid, ITC and Adani Ports were the major gainers. However, Tata Motors, Trent, Bajaj Finance and Asian Paints were among the laggards.

Pharma stocks slide as US headwinds hurt

Pharma stocks slide as US headwinds hurt

Rediff.com16 Sep 2025

Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.

Indian Pharma Majors Ready With Weight Loss Drugs

Indian Pharma Majors Ready With Weight Loss Drugs

Rediff.com12 Aug 2025

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

Sensex climbs 398 points on buying in RIL, IT counters

Sensex climbs 398 points on buying in RIL, IT counters

Rediff.com9 Oct 2025

Among Sensex firms, Tata Steel, HCL Tech, UltraTech Cement, Bharat Electronics, Sun Pharma and Tata Consultancy Services were the major gainers. However, Axis Bank, Titan, Maruti and Tata Motors were among the laggards.

'Sun Pharma offers the best medium- to long-term earnings growth visibility'

'Sun Pharma offers the best medium- to long-term earnings growth visibility'

Rediff.com3 Apr 2023

India's largest listed pharmaceutical (pharma) company - Sun Pharmaceutical Industries (Sun Pharma) - is expected to maintain its outperformance vis--vis the sector's, as its multiple bets on specialty products, improving product mix, recent acquisitions, and branded business are finding favour with brokerages. While it has gained 7 per cent over the past year, the Nifty Pharma Index is down 13.6 per cent. Its outperformance over two years has been fairly evident, with the market leader gaining 66 per cent to Nifty Pharma's minus 1.4 per cent.

Sensex, Nifty dive nearly 1% as HDFC Bank, RIL drag

Sensex, Nifty dive nearly 1% as HDFC Bank, RIL drag

Rediff.com22 Aug 2025

From the Sensex pack, Asian Paints, UltraTech Cement, Tata Steel, ITC, HCL Tech, Kotak Mahindra Bank, Adani Ports, Tata Consultancy Services, HDFC Bank and Tech Mahindra were among the major laggards. However, Mahindra & Mahindra, Maruti, Bharat Electronics and Sun Pharma were among the gainers.

Sensex jumps 555 pts on value buying, strong GDP data

Sensex jumps 555 pts on value buying, strong GDP data

Rediff.com1 Sep 2025

Among Sensex firms, Mahindra & Mahindra, Tata Motors, Trent, Eternal, Asian Paints and Infosys were the major gainers. However, Sun Pharma, ITC, Hindustan Unilever and Titan were among the laggards.

Sensex, Nifty tank nearly 1% on selling in pharma, IT shares

Sensex, Nifty tank nearly 1% on selling in pharma, IT shares

Rediff.com26 Sep 2025

Most pharma shares dropped, dragging the BSE Healthcare index down by 2.14 per cent after Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1. Wockhardt shares tanked 9.4 per cent.

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Sun Pharma's growth prospects look healthy; analysts positive on the stock

Rediff.com19 Jun 2023

Sun Pharmaceutical Industries (Sun Pharma) reported a turnaround in the January-March quarter of the 2022-23 financial year (Q4FY23), declaring a profit after tax (PAT) of Rs 1,984 crore versus a loss of Rs 2,277 crore in Q4FY22. However, that loss in FY22 was due to several exceptional one-time items -- with Rs 3,723.15 crore allocated to settlement of lawsuits in the US and other Exceptional Items adding up to Rs 3,935.75 crore. Adjusted for exceptional items, PAT in Q4FY22 amounts to Rs 2,155 crore, which is a year-on-year (YoY) growth of about 36 per cent.

Bulls prowl D-Street: Sensex jumps 716 points

Bulls prowl D-Street: Sensex jumps 716 points

Rediff.com1 Oct 2025

From the Sensex firms, Tata Motors jumped the most by 5.54 per cent, followed by Kotak Mahindra Bank, Trent, Sun Pharma, Axis Bank, and ICICI Bank. However, Bajaj Finance, State Bank of India, UltraTech Cement and Tata Steel were among the laggards.

Sensex climbs 329 points on global markets' rally

Sensex climbs 329 points on global markets' rally

Rediff.com25 Aug 2025

From the Sensex firms, Infosys, Tata Consultancy Services, HCL Tech, Tech Mahindra, Tata Motors, Sun Pharma, Maruti and Titan were among the major gainers. Bharat Electronics, Asian Paints, Bharti Airtel and ICICI Bank were among the laggards.

Despite profit-booking, Sensex, Nifty end higher

Despite profit-booking, Sensex, Nifty end higher

Rediff.com8 Sep 2025

Among Sensex firms, Tata Motors rose the most by 3.97 per cent. Mahindra & Mahindra jumped by 3.96 per cent. Maruti, Adani Ports, Bajaj Finance and UltraTech Cement were also among the gainers. However, Trent declined 3.81 per cent. Asian Paints, HCL Tech, Tech Mahindra, L&T, TCS, Power Grid and Sun Pharma were also among the laggards.

Sensex climbs 124 points; Nifty ends above 25K

Sensex climbs 124 points; Nifty ends above 25K

Rediff.com11 Sep 2025

Among Sensex firms, NTPC, Axis Bank, Power Grid, Bharti Airtel, Eternal and Sun Pharma were the major gainers. However, Infosys, Titan, UltraTech Cement and Hindustan Unilever were among the laggards.

Sensex ends down 119 points on profit-taking in IT, auto shares

Sensex ends down 119 points on profit-taking in IT, auto shares

Rediff.com15 Sep 2025

Among Sensex firms, Mahindra & Mahindra, Asian Paints, Infosys, Titan, Sun Pharma, Tata Consultancy Services, Tech Mahindra and Power Grid were the major laggards. However, Bajaj Finance, Eternal, UltraTech Cement and Reliance Industries were among the gainers.

Trump's 100% tariff on pharma unlikely to hurt domestic industry: Experts

Trump's 100% tariff on pharma unlikely to hurt domestic industry: Experts

Rediff.com26 Sep 2025

Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

Rediff.com12 Aug 2025

If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.

Sensex, Nifty end in red on concerns over US tariff

Sensex, Nifty end in red on concerns over US tariff

Rediff.com31 Jul 2025

Equity benchmark indices Sensex and Nifty ended lower on Thursday after US President Donald Trump announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1 and an unspecified penalty for buying Russian crude oil and military equipment.

Sun Pharma acquires US-based Pharmalucence

Sun Pharma acquires US-based Pharmalucence

Rediff.com16 Jul 2014

Drug major Sun Pharmaceutical Industries has acquired US-based Pharmalucence Inc for an undisclosed amount.

Sensex pares losses, ends up 64 points

Sensex pares losses, ends up 64 points

Rediff.com16 Jul 2025

Among Sensex firms, Mahindra & Mahindra, Tech Mahindra, State Bank of India, Infosys, Adani Ports and ITC were the major gainers. However, Eternal, Sun Pharma, Tata Steel, Tata Motors, Bajaj Finance and Bharat Electronics were among the major laggards.

Sensex tanks 586 points on global sell-off

Sensex tanks 586 points on global sell-off

Rediff.com1 Aug 2025

Tata Steel, Maruti, Tata Motors, Infosys, Bharti Airtel and Tech Mahindra were also among the laggards. However, Trent, Asian Paints, Hindustan Unilever, ITC, Kotak Mahindra Bank, and Reliance Industries were the gainers.

Sensex tanks 721 pts dragged by Bajaj Finance, foreign fund outflows

Sensex tanks 721 pts dragged by Bajaj Finance, foreign fund outflows

Rediff.com25 Jul 2025

Stock markets declined for the second day in a row on Friday, with the Sensex tumbling 721 points due to heavy selling in financial, IT and oil & gas shares amid persistent foreign fund outflows.

Blue-chip stocks drag Sensex down by 542 points

Blue-chip stocks drag Sensex down by 542 points

Rediff.com24 Jul 2025

From the Sensex firms, Trent, Tech Mahindra, Bajaj Finserv, Reliance Industries, Infosys, Kotak Mahindra Bank, HCL Technologies, and NTPC were among the biggest laggards. However, Eternal, Tata Motors, Sun Pharma, Tata Steel, and Titan were the gainers.

Stock markets end lower amid Israel-Iran conflict, rising crude oil prices

Stock markets end lower amid Israel-Iran conflict, rising crude oil prices

Rediff.com17 Jun 2025

From the Sensex pack, Sun Pharma, Eternal, Tata Motors, Bajaj Finance, IndusInd Bank and Bajaj Finserv were among the major laggards. In contrast, Tech Mahindra, Infosys, Asian Paints and Maruti were among the gainers.

Buying in L&T helps Sensex gain 144 points

Buying in L&T helps Sensex gain 144 points

Rediff.com30 Jul 2025

Sun Pharma, NTPC, Maruti, Bharti Airtel, Trent and Axis Bank were also among the gainers. However, Tata Motors, Power Grid, Eternal, Bajaj Finserv and Hindustan Unilever were among the laggards.

Sun Pharma's Dilip Shanghvi takes 99% pay cut

Sun Pharma's Dilip Shanghvi takes 99% pay cut

Rediff.com2 Aug 2019

As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.

Sun Pharma recalls over 34k bottles of generic drug in US

Sun Pharma recalls over 34k bottles of generic drug in US

Rediff.com11 Feb 2023

Drug major Sun Pharma is recalling over 34,000 bottles of a generic medication, used to treat high blood pressure, in the US market due to failed dissolution testing. As per the US Food and Drug Administration's Enforcement Report, the US-based arm of Sun Pharmaceutical Industries is recalling lots of Diltiazem Hydrochloride extended-release capsules which are used to treat angina, high blood pressure and some types of irregular heartbeats.

Sensex, Nifty rebound nearly 1% on value buying

Sensex, Nifty rebound nearly 1% on value buying

Rediff.com16 Jun 2025

Among 30 Sensex firms, UltraTech Cement, Tech Mahindra, HCL Tech, Tata Consultancy Services, Eternal, Asian Paints, Tata Steel and Kotak Mahindra Bank were among the biggest gainers. Tata Motors, Adani Ports and Sun Pharma were the laggards.

Daiichi Sankyo to offload stake in Sun Pharma

Daiichi Sankyo to offload stake in Sun Pharma

Rediff.com20 Apr 2015

Daiichi won't remain a major shareholder in Sun Pharma.

How the markets will fare this week

How the markets will fare this week

Rediff.com27 Jul 2025

Stock markets are in for an event-heavy week ahead with a raft of Q1 earnings from blue-chips, the US Fed interest rate decision and foreign investors trading activity driving investors' sentiment, analysts said. Macroeconomic data announcements, monthly auto sales numbers and global market trends would also guide movement in the domestic equities, they said.

Sun Pharma surpasses SBI in market valuation

Sun Pharma surpasses SBI in market valuation

Rediff.com17 Mar 2015

TCS is the most valued Indian company.

Why Daiichi's exit is good for Sun Pharma

Why Daiichi's exit is good for Sun Pharma

Rediff.com22 Apr 2015

But splitting management bandwidth by investing in non-core businesses will not be appreciated by the market in the long run.

Sensex surges over 769 pts as FMCG, power shares gain

Sensex surges over 769 pts as FMCG, power shares gain

Rediff.com23 May 2025

From the Sensex firms, Eternal, Power Grid, ITC, Bajaj Finserv, Nestle, Axis Bank, Kotak Mahindra Bank and Adani Ports were among the biggest gainers. Sun Pharma was the only laggard, declining nearly 2 per cent.

Sensex gains 300 pts on fresh foreign fund inflows and buying in ICICI Bank, RIL

Sensex gains 300 pts on fresh foreign fund inflows and buying in ICICI Bank, RIL

Rediff.com27 Jun 2025

From the Sensex pack, Asian Paints, UltraTech Cement, Power Grid, ICICI Bank, Reliance Industries, Hindustan Unilever, Bharat Electronics and Sun Pharma were among the major gainers. In contrast, Trent, Eternal, Axis Bank and Titan were among the laggards.

Norms: US drug regulator warns Sun Pharma

Norms: US drug regulator warns Sun Pharma

Rediff.com1 Sep 2010

The United States Food and Drug Administration has issued a warning letter to it for manufacturing practice violations at its Cranbury facility in New Jersey.

Sun Pharma claims victory over Taro

Sun Pharma claims victory over Taro

Rediff.com8 Sep 2010

Sun Pharma, which was fighting a takeover battle with Israeli pharma major Taro, on Wednesday said that the Supreme Court of Israel has given the ruling in favour of the company.

Foreign fund inflows, ICICI Bank and RIL boost markets

Foreign fund inflows, ICICI Bank and RIL boost markets

Rediff.com5 Jun 2025

Eternal was the biggest gainer in the Sensex pack, jumping 4.50 per cent, followed by Power Grid, ICICI Bank, Reliance Industries, UltraTech Cement, Adani Ports, Sun Pharma, ITC and Hindustan Unilever were also among the winners. In contrast, IndusInd Bank, Axis Bank, Bajaj Finserv and Bajaj Finance were among the laggards.

Sun Pharma open to large acquisitions post Ranbaxy

Sun Pharma open to large acquisitions post Ranbaxy

Rediff.com25 Mar 2015

Sun Pharma open to large acquisitions post Ranbaxy.

Sun Pharma sues Novartis in US court

Sun Pharma sues Novartis in US court

Rediff.com13 Jun 2013

In a development that could hasten the entry of the generic version of Gleevec into the US market, Indian drug major Sun Pharma has sued Novartis Pharmaceuticals Corp in the District Court of New Jersey, demanding rights to launch a generic version of the cancer drug before the Novartis patent expires.